Rights and permissions
About this article
Cite this article
Targeted CMV prophylaxis with valganciclovir viable. Pharmacoecon. Outcomes News 314, 7 (2001). https://doi.org/10.1007/BF03280347
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03280347